HealthThe Motley Foolabout 13 hours ago
Pfizer Monthly Weight-Loss Drug Threatens Rivals
1 min read
Pfizer's experimental weight-loss drug berobenatide requires only a monthly injection, unlike weekly shots from Novo Nordisk and Eli Lilly. Phase 2b trials showed comparable results. The market could reach $150 billion annually by 2035. Pfizer's drug offers convenience and scalability advantages.
Level
Hype check
Tap to vote and see what everyone thinks.
